ImmPort Study ID	PubMed	Study Title	PI	Biosample ID	Experiment ID	Cohort	Repository Accession	Type	Subtype	Biosample Name	Biosample Description	Species	Strain	Cancer Type	Tissue	Cell Type	Cell Line	Treatment
GSE64771	25605014	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer	None	SRX833873	GSE64771	Orthotopic Tumor	GSM1580362	Prostate Cancer	Prostate Adenocarcinoma (PRAD)	Androgen Sensitive Primary Orthotopic Tumor (RS-01574309)	None	Mus musculus	Androgen Sensitive Primary Orthotopic Tumor (RS-01574309)	Prostate Cancer	None	None	None	None
GSE64771	25605014	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer	None	SRX833874	GSE64771	Orthotopic Tumor	GSM1580363	Prostate Cancer	Prostate Adenocarcinoma (PRAD)	Androgen Sensitive Met (matched) (RS-01574310)	None	Mus musculus	Androgen Sensitive Met (matched) (RS-01574310)	Prostate Cancer	None	None	None	None
GSE64771	25605014	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer	None	SRX833875	GSE64771	Orthotopic Tumor	GSM1580364	Prostate Cancer	Prostate Adenocarcinoma (PRAD)	Androgen Sensitive Primary Orthotopic Tumor (RS-01574311)	None	Mus musculus	Androgen Sensitive Primary Orthotopic Tumor (RS-01574311)	Prostate Cancer	None	None	None	None
GSE64771	25605014	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer	None	SRX833876	GSE64771	Orthotopic Tumor	GSM1580365	Prostate Cancer	Prostate Adenocarcinoma (PRAD)	Androgen Sensitive Met (matched) (RS-01574312)	None	Mus musculus	Androgen Sensitive Met (matched) (RS-01574312)	Prostate Cancer	None	None	None	None
GSE64771	25605014	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer	None	SRX833877	GSE64771	Orthotopic Tumor	GSM1580366	Prostate Cancer	Prostate Adenocarcinoma (PRAD)	Castrate Resistant Primary Orthotopic Tumor (RS-01580057)	None	Mus musculus	Castrate Resistant Primary Orthotopic Tumor (RS-01580057)	Prostate Cancer	None	None	None	None
GSE64771	25605014	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer	None	SRX833878	GSE64771	Orthotopic Tumor	GSM1580367	Prostate Cancer	Prostate Adenocarcinoma (PRAD)	Castrate Resistant Met (matched) (RS-01580058)	None	Mus musculus	Castrate Resistant Met (matched) (RS-01580058)	Prostate Cancer	None	None	None	None
GSE64771	25605014	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer	None	SRX833879	GSE64771	Orthotopic Tumor	GSM1580368	Prostate Cancer	Prostate Adenocarcinoma (PRAD)	Castrate Resistant Primary Orthotopic Tumor (RS-01580059)	None	Mus musculus	Castrate Resistant Primary Orthotopic Tumor (RS-01580059)	Prostate Cancer	None	None	None	None
GSE64771	25605014	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer	None	SRX833880	GSE64771	Orthotopic Tumor	GSM1580369	Prostate Cancer	Prostate Adenocarcinoma (PRAD)	Castrate Resistant Met (matched) (RS-01580060)	None	Mus musculus	Castrate Resistant Met (matched) (RS-01580060)	Prostate Cancer	None	None	None	None
